Bryan Hubbard has written about ibogaine in What Doctors Don't Tell You — the UK health publication he co-edits — reaching readers who encounter the medicine nowhere in mainstream health reporting. His coverage identifies what the evidence shows: ibogaine interrupts addiction, PTSD, and treatment-resistant depression through mechanisms no current pharmaceutical directly addresses. What it cannot determine is whether a specific reader is an appropriate candidate for ceremony.
Bryan Hubbard is a UK health journalist and co-editor of What Doctors Don't Tell Youwho has written about ibogaine's application to addiction and trauma. Ibogaine acts through GDNF upregulation, NMDA antagonism, and opioid receptor reset — mechanisms no approved treatment directly addresses. The 2023 Stanford study found 88% reductions in PTSD symptoms at one month in 30 special operations veterans. Cardiac screening including 12-lead EKG is required before any ceremony. SSRIs are an absolute contraindication.
Who Bryan Hubbard Is and What His Advocacy Covers
Bryan Hubbard is a UK health journalist, author, and co-editor of What Doctors Don't Tell You — a UK publication focused on medical topics that conventional health journalism tends not to cover. He has written about ibogaine in the context of addiction treatment and trauma, bringing the medicine to British readers who would not encounter it in the mainstream press.
His coverage is part of a wider pattern. In the United States, veterans' advocate and former Navy SEAL Shawn Ryan has spoken publicly about ibogaine for PTSD. Conor McGregor discussed it in the context of alcohol recovery. Joe Rogan's podcast has covered it multiple times. Each has introduced ibogaine to a different audience — veterans, sports followers, mainstream podcast listeners, UK health readers. The effect has been a significant increase in public awareness of a treatment that peer-reviewed research has been quietly documenting for decades.
That increase in awareness is, in itself, useful. Ibogaine is underrecognised relative to what the evidence shows — a consequence of its Schedule I status in the United States, established in 1970 before clinical research existed. The people who find it through advocacy journalism often have conditions — opioid dependence, PTSD, treatment-resistant depression — that conventional treatment has not resolved. The advocacy is not wrong about the medicine. What it cannot do is assess the medical candidacy of its readers.
What the Stanford Research Found
In February 2023, Nature Medicine published a Stanford University study examining ibogaine in 30 male special operations veterans with treatment-resistant PTSD, traumatic brain injury, or both. All participants had prior treatment exposure — medication, therapy, veterans programme participation — and had not achieved adequate resolution.
At one month after a single ibogaine administration, the study found:
- 88% reduction in PTSD symptom scores
- 87% reduction in depression symptom scores
- 81% reduction in anxiety symptom scores
- Significant improvements in cognitive function and functional disability ratings
The study did not include a placebo arm. Thirty participants is not a definitive clinical population. These are genuine methodological limitations. The numbers stand on their own with the caveats included — and the direction of the evidence is consistent with what smaller studies have observed across different populations for decades.
Following the Stanford publication, four Texas universities — UTMB, UTHealth Houston, Texas A&M, and Baylor — committed $50 million USD to follow-up clinical trials. That is not a small or speculative investment.
For more detail on the PTSD-specific research, the ibogaine for PTSD guide covers the mechanism and the broader clinical literature beyond the Stanford paper.
The Mechanism the Coverage Gets Right
The mechanism is where advocacy coverage has done genuinely useful work. Ibogaine acts through pathways that no approved pharmaceutical directly touches.
The most significant is GDNF (glial cell line-derived neurotrophic factor) upregulation. GDNF is depleted in people with chronic substance use disorders, PTSD, and treatment-resistant depression. Ibogaine appears to restore it at levels no current pharmaceutical achieves — which is why the neuroplasticity window following ceremony is distinct from anything SSRIs or ketamine produce. As documented in MAPS ibogaine research summaries, ibogaine's GDNF effects are durable — noribogaine, ibogaine's primary active metabolite, remains pharmacologically present for weeks to months after ceremony.
The second mechanism is NMDA receptor antagonism. Ibogaine disrupts glutamate transmission patterns that maintain anxiety responses and traumatic memory consolidation. This is mechanistically related to how ketamine works for treatment-resistant depression, but with a more complex receptor profile: ibogaine acts simultaneously on opioid receptors, sigma-2 receptors, the serotonin transporter, and NMDA channels. The combination creates a window in which existing neural patterns are less fixed than normal — the substrate on which ceremony and integration work.
The third is opioid receptor reset. In opioid-dependent individuals, ibogaine's interaction with kappa and mu opioid receptors interrupts physical withdrawal within hours. This is why the medicine has historically attracted research attention specifically for opioid dependence — and why it has been sought by people for whom methadone and buprenorphine were not adequate. For more on the addiction-specific mechanism, the iboga for addiction guide covers the GDNF and reward-circuit evidence in more detail.
Ibogaine's unusual pharmacology — acting on four receptor systems simultaneously — is also what makes it require medical oversight. The cardiac effects, specifically QT interval prolongation, are real and measurable. They are manageable with appropriate screening and monitoring. They are dangerous without it.
What the Coverage Tends to Omit
Advocacy journalism has a characteristic gap. It presents the mechanism and the outcomes. It rarely communicates the specific conditions that would make a given reader an inappropriate candidate — or what happens when ceremony proceeds without the infrastructure to manage cardiac risk.
The people who find ibogaine through Hubbard's writing, Shawn Ryan's podcast, or Joe Rogan's platform tend to be people who have tried everything else. SSRIs that blunted rather than resolved. Therapy that circled without landing. Abstinence programmes that held for months, then did not. By the time they encounter ibogaine advocacy, many have spent years accumulating evidence that conventional treatment is not sufficient. That history tends to produce people who are genuinely ready to encounter what the medicine shows them — and who may also be in the most urgent need of a careful medical assessment before proceeding.
Integration is the part of the picture that advocacy coverage most consistently omits. The ceremony opens a neuroplasticity window — elevated GDNF and BDNF create conditions in which new patterns are more possible. That window does not stay open indefinitely. What happens in it determines whether anything lasting results. Providers who hand people the medicine and wish them luck are not providing ibogaine treatment — they are providing ibogaine. The distinction matters: the research shows outcomes from structured programmes with integration support, not from isolated ceremony.
For what the full programme involves, the ceremony page describes what medical screening, preparation, and the integration period actually require at Transcend.
Who Is Not an Appropriate Candidate
This is the section the coverage Hubbard's readers will not encounter.
The following are absolute contraindications for ibogaine ceremony. They are not preferences or recommendations — they are conditions under which ibogaine produces unacceptable cardiac or pharmacological risk:
- QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction. Ibogaine extends the QT interval. In a person with pre-existing QT prolongation, this can produce life-threatening arrhythmia. This is identified by a 12-lead EKG before ceremony — not during it.
- Current SSRIs or SNRIs without a completed supervised taper. The combination of ibogaine and serotonergic medications can produce serotonin syndrome. This is potentially fatal. There are no exceptions to this rule. The taper timeline varies by medication and is non-negotiable.
- Severe liver or kidney disease. Ibogaine is hepatically metabolised. Significant liver disease impairs clearance and amplifies cardiac risk. Blood panel results are required before any ceremony date is confirmed.
- Active psychosis or schizophrenia-spectrum disorder. Ibogaine's visionary phase involves intense internally-generated content. In a person with active psychosis, this amplifies rather than resolves the underlying condition.
- Methadone without a completed transition protocol. Methadone has an extended half-life and its own cardiac effects. The combination with ibogaine requires a specific transition — not simply cessation.
- Lithium and certain other psychiatric medications.The specific medication list is reviewed during the intake process. Ibogaine's receptor profile interacts with multiple psychiatric medications in ways that require individual assessment.
- Pregnancy. An absolute contraindication.
- Acute psychiatric crisis. The experience amplifies what is present. Entering ceremony in a state of acute instability does not produce stability. Someone in acute crisis may be appropriate for iboga at a later point — after stabilisation — but is not an appropriate candidate at this moment, regardless of how long they have been looking for something that works.
The intake process is where these factors are assessed. The FAQ covers what medical screening involves in more detail. A medical history, EKG, blood panel, and full medication review are required before any ceremony date is confirmed. Some contraindications are permanent. Some require preparation that takes weeks or months. None are waived because someone has been searching for a solution for a long time.
Is This Right for You?
If you found ibogaine through Bryan Hubbard's writing, through Shawn Ryan's podcast, or through any other form of advocacy coverage, the question that coverage raises — is this something I should explore? — is a reasonable one. The mechanism is real. The research is consistent. For people with treatment-resistant conditions, ibogaine produces outcomes that conventional treatment has not.
The next step is not booking a ceremony. It is establishing whether you are an appropriate candidate for one. That requires a conversation, a medical history review, and screening results — not an article.
The application process at Transcend begins with a personal response within 2–3 business days. The screening conversation establishes candidacy first. For people who are appropriate candidates, the integration support offered in the weeks following ceremony is what determines whether the neuroplasticity window translates into lasting change.
If you are not an appropriate candidate, we will tell you — directly and without softening it. We would rather lose a potential participant than put someone at risk.